Company Overview of Naurex, Inc.
Naurex, Inc., a clinical-stage company, develops novel therapies for psychiatry and neurology disorders for modulating the N-methyl-D-aspartic acid receptor (NMDAR). It offers novel chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The company provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. It offers its products for central nervous system conditions, including depression, anxiety disorders, cognitive disorders, pain, and addiction. Naurex, Inc. was founded in 2006 and is based in Evanston, Illinois.
1801 Maple Avenue
Evanston, IL 60201
Founded in 2006
Key Executives for Naurex, Inc.
Naurex, Inc. Key Developments
Similar Private Companies By Industry
|Akashi Therapeutics, Inc.||United States|
|Professional Packaging Corp.||United States|
|Cingulate Therapeutics LLC||United States|
|Claragen, Inc.||United States|
|Arcadia Rx LLC||United States|
Recent Private Companies Transactions
November 21, 2014
To contact Naurex, Inc., please visit www.naurex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.